Filters

Documents containing drug

Showing 25 of 65 items meeting your criteria.

Type	Category	Supplier

Cancer Bioreagents Cancer remains one of the most active areas of biomedical research, driving continuous advances in immunotherapy, targeted therapeutics, biomarker discovery, and precision medicine. To support cancer research from basic biology to translational studies, Abnova offers a comprehensive portfolio of antibodies, recombinant proteins, and ELISA kits covering key oncology pathways and targets. This catalog highlights antibodies, recombinant proteins, and ELISA kits supporting research in Immuno-Oncology, Cell Therapy, Targeted Therapy, Biomarkers, DNA Repair, Tumor Microenvironment, Cell Signaling, Cancer Stem Cells, Tumor Suppressors, Cell Death, Hematologic Oncology, and Cancer Metabolism. Our products are designed to support studies in tumor biology, immune regulation, therapeutic target validation, biomarker development, and drug discovery.
Documents	Cancer	Abnova Corporation	View
Biosimilar and Immunogenicity Research Tools Biologics development requires accurate quantification and reliable immunogenicity assessment to ensure safety and efficacy. Abnova provides Biosimilar and Immunogenicity Research Tools to support key workflows from drug measurement to immune response evaluation. Abnovas portfolio includes biosimilar antibodies and ELISA kits for comparative and PK studies, as well as ADA reagents and ELISA kits for immunogenicity assessment. These solutions provide high sensitivity and reproducibility, enabling efficient and consistent research outcomes.
Documents	Immunology	Abnova Corporation	View
Whitepaper - Storage of liver organoids at room temperature using WellReady The use of organoids for disease modelling, drug discovery and personalised medicine has become increasingly popular. Processes for the generation and maintenance of organoids can be complex, requiring high technical awareness. Additionally, some organoid models are unsuitable for storage and shipment by freeze/thaw. WellReady™offers a simple solution to these challenges, allowing for the shipment of developed organoid models at ambient temperatures, supplying the end-user with a ready to use model.
Documents	Sample Preservation	Atelerix	View
Collagen Hybridizing Peptides (CHPs) in Pancreatic Ductal Adenocarcinoma (PDAC) Research T he dense stromal reaction in PDAC, rich in collagen, profoundly impacts tumor progression and drug delivery. Aberrant collagen remodeling is a hallmark of this aggressive cancer. Collagen Hybridizing Peptides (CHPs), with their unique ability to target denatured collagen, offer a powerful tool to visualize and quantify these critical structural changes within the PDAC microenvironment. This technology can enhance our understanding of stromal biology and potentially identify novel therapeutic strategies.
Documents	Peptides	3Helix	View
Collagen Hybridizing Peptides (CHPs) Applications in nAMD Research The ability of CHPs to specifically target and visualize active fibrosis offers several important implications for nAMD research. Firstly, they serve as a novel tool for understanding the dynamics of fibrosis in the disease process, potentially identifying key stages for intervention. Secondly, CHPs can accelerate the development of new anti-fibrotic treatments by providing a direct and quantifiable measure of drugefficacy in preclinical studies. Finally, while currently primarily used in animal models, the potential exists to translate CHP technology into diagnostic tools for human patients, allowing for earlier detection and monitoring of subretinal fibrosis, which could ultimately lead to improved treatment strategies and visual outcomes.
Documents	Peptides	3Helix	View
Biopredic Overview Biopredic are a biotechnology company specializing in the design and manufacture of human and animal assay systems. Their solutions for Drug, Cosmetic, and Chemical development and testing are focused on liver, skin and blood.
Documents	Supplier Introduction	Biopredic	View
Endocrinology and Metabolism TargetMol, as a professional one-stop platform for drug discovery, offers a variety of products related to Endocrinology and Metabolism.
Documents	Metabolism	TargetMol	View
High Throughput Screening HTS, which emerged in the 1990s, is a new model for drug discovery that integrates advanced technology in chemistry, biology, bioinformatics and automation.
Documents	Drug Discovery	TargetMol	View
Cardiovascular Diseases As a one-stop drug screening expert, TargetMol offers stable products with a wide variety, providing a range of inhibitors & agonists, recombinant proteins, compound libraries and drug-like compound libraries related to cardiovascular diseases.
Documents	Cardiovascular	TargetMol	View
Computer-Aided Drug Design and AI-Driven Drug Discovery Computer-Aided Drug Design (CADD) is a technology that utilises computer techniques to discover and optimise active lead compounds into candidate drugs. Artificial Intelligence-Driven Drug Discovery (AIDD) utilises AI technology to improve the efficiency and success rate of the drug discovery and design process.
Documents	Drug Discovery	TargetMol	View
Drug-Like Compounds Drug-Like Compounds, as a class of small molecules with drug potential, serve as an important source for small-molecule drug discovery. They are typically derived from existing drugs through structural modifications or improvements to achieve better efficacy or reduce adverse effects. Drug-like compounds help researchers gain insights from existing drugs, enabling the rapid development of novel therapeutics and improving research and development efficiency.
Documents	Small Molecules	TargetMol	View
Inhibitory Antibodies TargetMol currently offers more than 3,000 inhibitory antibody products, including biosimilar antibodies, bispecific antibodies, antibody-drug conjugates (ADCs) and anti-mouse/anti-rat in vivo antibodies.
Documents	Antibodies	TargetMol	View
PPI Modulator Virtual Screening Service Protein-protein interactions (PPIs) are the cornerstone of life processes and a "goldmine" of targets for next-generation drug development. Yet, PPI-targeted drug discovery often hits a wall: groundbreaking mechanisms are identified, but validated lead compounds remain elusive—leaving researchers with "no ingredients to cook with."
Documents	Service	TargetMol	View
Molecular Biology Reagents Founded in 2018 as an academic spin-off based on unique DIANA technology for drug discovery and diagnostics, bringing deep expertise in molecular biology, chemistry and informatics. All operations are based in the heart of Europe: Prague, Czech Republic. With our expertise in protein engineering, we develop and produce unique and high-performance reagents for PCR, RT-PCR, RNA production, NGS and sample preparation in research, development and diagnostics.
Documents	Catalogue	DIANA Biotechnologies	View
High-Quality Protein Raw Materials Cloud-Clone provides high-quality raw materials to support global new drug development, biopharmaceutical companies, diagnostic reagent manufacturers, and CROs.
Documents	Proteins	Cloud-Clone Corp.	View
Neuroscience Brochure Empowering your neuroscience research. Accelerating drug discovery, development and translation for nervous system disorders.
Documents	Neuroscience	iXCells Biotechnologies	View
Cryopreserved Leukopaks and Primary Cells Support Timely Experiment Set-Up and Reduce Drug Development Costs Leukopaks provide enriched peripheral blood mononuclear cells (PBMCs)with low granulocytes and red blood cells. They are a vital source material forimmunological studies, cell therapy research, and pharmaceuticaldevelopment. The collection and processing of the material requires tightcoordination between the sourcing and laboratory teams to collect, processand cryopreserve large number of samples within the ideal time of less than 24hours. Here, we demonstrate that by cryopreserving Leukapheresis materialand primary cells logistical issues are eliminated, providing convenience inthe timing of experiments, lowering costs of research and development of newtherapies, and allowing future access to same lot samples for additionalstudies. However, the impact of cryopreservation of Leukopaks and primarycells efficacy have been mixed. To demonstrate the shelf life of cryopreservedLeukopaks we performed a year long stability study demonstrating that theviability of the products remains above 95% post-thaw. We also performedbulk isolations of primary cells such as MNCs, CD3+ T Cells and CD56+ NKcells from 10 Billion TNC Leukopaks, from 20 donors to demonstrate anaverage cost saving initiative for the biotech industry of about $57K per donorfor the MNC isolation, $91K per donor for the CD3+T Cell isolation, and$12K per donor for the CD56+ NK Cell isolation.
Documents	Biological Samples	CGT Global	View
Detection of Mitophagy with Keima-Red Mitophagy can be detected and visualised due to the changes in the excitation spectrum of mKeima-Red before and after induction of mitophagy by drug treatment.
Documents	Proteins	Medical & Biological Laboratories (MBL)	View
VLP & Nanodisc Displayed Antigens KACTUS has developed a catalogue of full-length multipass transmembrane proteins displayed on virus-like particles (VLPs) or copolymer nanodiscs for immunisation, affinity testing, PK/PD studies, antibody characterisation and other drug discovery applications.
Documents	Proteins	KactusBio Inc.	View
Cas9 Expressing Primary Cells & GPCR Expressing Cell Lines Neuromics is proud to introduce their newest pioneering research tools - human Cas9 expressing primary cells and GPCR expressing cell lines. With these modifications, the cells are valuable and versatile options for drug discovery, studying disease mechanisms, and countless other applications.
Documents	Primary Cells	Neuromics	View
Recombinant Protein Catalogue KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, biologics and cell therapy. Their expansive catalog, boasting over 3000 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of their product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.
Documents	Catalogue	KactusBio Inc.	View
GPCR VLPs & Nanodiscs for Drug Discovery Poster G protein-coupled receptors (GPCRs), also known as seven-transmembrane receptors, represent the most important class of drug targets. However, extraction and purification of membrane proteins like GPCRs, ion channels, and transporters are generally challenging due to low expression levels and the hydrophobic nature of transmembrane segments. To tackle this challenge, we have engineered and produced GPCRs in VLP and/or nanodisc formats, which have been successfully applied to GPCR antibody drug discovery and various in vitro assays.
Documents	Drug Discovery	KactusBio Inc.	View
Solute Carrier Proteins KACTUS offers custom full-length solute carrier protein expression services displayed on VLPs or nanodiscs for various drug discovery applications.
Documents	Proteins	KactusBio Inc.	View
Drug Repurposing TargetMols Drug Repurposing Compound Library, containing 4900+ approved and clinical drugs, has undergone extensive preclinical studies and have well-characterised bioactivities, safety and bioavailability.
Documents	Drug Discovery	TargetMol	View
Neurodegenerative Diseases As a leading supplier in the field of drug discovery, TargetMol offers various products related to neurodegenerative diseases including active compounds, compound libraries and recombinant proteins.
Documents	Neuroscience	TargetMol	View

Next Last Show Max.